Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-06

Clinical Trial Update: The Effect of Ixazomib on the Latent HIV Reservoir [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ixazomib for reducing the latent HIV reservoir; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ixazomib (ixazomib)

Snippet

Sponsor: Mayo Clinic | Conditions: Human Immunodeficiency Virus (HIV) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-01-06